[EVENT] ASCO Annual Meeting

Join Ipsos Healthcare’s Marco Dibonaventura who will be presenting at this year’s conference dedicated to the brightest minds of oncology. Dr. Marco DiBonaventura, Ph.D. Head of Global Evidence Value and Access will discuss Value Frameworks and Physician Perceptions in Oncology. His talk will include high priority topics such as...

Women who are younger, have lower income and are ethnically non-white are more likely to be non-adherent to oral endocrine therapy (ET) for breast cancer. The new research, conducted by Kantar Health and drawn from its National Health and Wellness Survey (NHWS), will be presented today at the 21st Annual International Meeting for ISPOR (International Society for Pharmacoeconomics and Outcomes Research) in Washington, D.C.

As breast cancer survivorship increases, maintenance treatments such as adjuvant ET, including tamoxifen or aromatase inhibitors, are critical to improving long-term survival.

According to NHWS data, adherence predictors varied based on whether the non-adherence was unintentional or intentional. NHWS research found that:

• Patients who are unintentionally non-adherent, such as forgetting to take their medication, are more likely to be non-white, obese, sedentary and smokers.
• Patient who are intentionally non-adherent, such as not getting a prescription filled or deliberately skipping doses, have lower income and normal BMI.
• Younger patients are more likely to be non-adherent, both intentionally and unintentionally.

For conference details, please visit the ASCO website.

The Global Oncology Therapy Monitor is the world’s most comprehensive syndicated database of cancer treatment. The database covers over 200 different types of cancer, over 60 different organs in which it can occur, and a myriad of genes and proteins that are linked to malignancies. Our team of oncology experts have a deep understanding of the oncology landscape and the competitive environment.